Literature DB >> 1336152

Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

D P Hanger1, K Hughes, J R Woodgett, J P Brion, B H Anderton.   

Abstract

Glycogen synthase kinase-3 (GSK-3) reduced the mobility of human tau on SDS-PAGE, prevented binding of the monoclonal antibody (mAb), Tau.1, and induced binding of the mAb 8D8. Recombinant tau phosphorylated by GSK-3 aligned on SDS-PAGE with the abnormally phosphorylated tau (PHF-tau) associated with the paired helical filaments in Alzheimer's disease brain. Phosphorylated serine396 (numbering of the largest human brain tau isoform) was identified as a binding site on tau for mAb 8D8. The localisation of GSK-3 within granular structures in pyramidal cells indicates that GSK-3 alpha and GSK-3 beta may have a role in the production of PHF-tau in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336152     DOI: 10.1016/0304-3940(92)90774-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  190 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

2.  Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner.

Authors:  Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

3.  MMFPh: a maximal motif finder for phosphoproteomics datasets.

Authors:  Tuobin Wang; Arminja N Kettenbach; Scott A Gerber; Chris Bailey-Kellogg
Journal:  Bioinformatics       Date:  2012-04-23       Impact factor: 6.937

Review 4.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 5.  Tau in neurodegenerative diseases: tau phosphorylation and assembly.

Authors:  J Avila; M Pérez; F Lim; A Gómez-Ramos; F Hernández; J J Lucas
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

6.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

Authors:  Wendy Noble; Emmanuel Planel; Cindy Zehr; Vicki Olm; Jordana Meyerson; Farhana Suleman; Kate Gaynor; Lili Wang; John LaFrancois; Boris Feinstein; Mark Burns; Pavan Krishnamurthy; Yi Wen; Ratan Bhat; Jada Lewis; Dennis Dickson; Karen Duff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-02       Impact factor: 11.205

7.  Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

Authors:  Monica Javidnia; Michaeline L Hebron; Yue Xin; Nikolas G Kinney; Charbel E-H Moussa
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 8.  Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders.

Authors:  J R Woodgett
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

9.  Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms.

Authors:  C Laura Sayas; Jesús Avila; Francisco Wandosell
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.